If you have been reading about synthetic peptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
=== Recreational === Benzydamine has been used recreationally. If taken in excess amounts, it acts as an atypical deliriant and CNS stimulant. Such use, particularly among teenagers, has been reported in Brazil, Poland, Romania, and Turkey.
==== India ==== Recent economic growth has led to development of new categories of alcohol in India. Cider is one such category. New product launches are seen in almost all metropolitan cities. Also a filtered non-alcoholic carbonated apple juice called "Appy Fizz" was introduced by Parle in India in 2005 and it became an instant hit. Recently, they have decided to push the brand beyond the ₹10 billion mark ($97.5 million).
=== Infection === Stomach acid plays a role in killing ingested bacteria. Use of pantoprazole may increase the chance of developing infections such as pneumonia, particularly in hospitalized patients.
Early attempts to create alien-human hybrids were pioneered by German and Japanese scientists shortly after World War II, and for some time during the Cold War. However, these often met with failure, and the Syndicate started to rely more on their own scientists. According to the Alien Bounty Hunter, in the 1950s, Soviet geneticists found a unique genetic anomaly within identical twins. The Colonists and Syndicate scientists used this to eventually develop human clones with alien elements and partial hybrids, but they were still ultimately inferior. Hybrids of this type include Samantha Mulder, Kurt Crawford, the Gregors, Ernest Calderon, and Dr. William Secare. Child and adult versions of Samantha and Kurt are also seen. These clones have the same caustic greenish blood of the aliens, have greater muscular strength and higher physical endurance levels than most normal humans, and can breathe underwater. In addition to their intended use by the alien colonists, the Syndicate is occasionally seen using these clones to perform various tasks, such as research and physical labor. The pinnacle of the project is Cassandra Spender (Veronica Cartwright), mother of Jeffrey Spender (Chris Owens) and ex-wife of The Smoking Man. Cassandra is a hybrid created through a process other than cloning, and worked on by both the Syndicate and the aliens themselves, although the exact methods used to transform her are never fully revealed. The experiment presumably began when she, along with other family members of the Syndicate, were turned over to the colonists in 1973.
Sources: en.wikipedia.org
As demand for consumer goods increased after World War II, the resulting shortage helped overcome lingering resistance to the purchase of German products. At the time, Germany had a large pool of skilled and cheap labour, partly as a result of the flight and expulsion of Germans from Central and Eastern Europe, which affected up to 16.5 million Germans. This helped Germany to more than double the value of its exports during the war. Apart from these factors, hard work and long hours at full capacity among the population and in the late 1950s and 1960s extra labour supplied by thousands of Gastarbeiter ("guest workers") provided a vital base for the economic upturn. This would have implications later on for successive German governments as they tried to assimilate this group of workers. With the dropping of Allied reparations, the freeing of German intellectual property and the impact of the Marshall Plan stimulus, West Germany developed one of the strongest economies in the world, almost as strong as before the Second World War. The East German economy showed a certain growth, but not as much as in West Germany, partly because of continued reparations to the USSR. In 1952, West Germany became part of the European Coal and Steel Community, which would later evolve into the European Union. On 5 May 1955 West Germany was declared to have the "authority of a sovereign state". The British, French and US militaries remained in the country, just as the Soviet Army remained in East Germany.
==== MeSH D12.776.964.700.750 – retroviridae proteins, oncogenic ==== MeSH D12.776.964.700.750.320 – fusion proteins, gag-onc MeSH D12.776.964.700.750.320.700 – oncogene protein p65(gag-jun) MeSH D12.776.964.700.750.470 – gene products, rex MeSH D12.776.964.700.750.480 – gene products, tax (gene) MeSH D12.776.964.700.750.650 – oncogene protein gp140(v-fms) MeSH D12.776.964.700.750.710 – oncogene protein p21(ras) MeSH D12.776.964.700.750.750 – oncogene protein p55(v-myc) MeSH D12.776.964.700.750.760 – oncogene protein pp60(v-src) MeSH D12.776.964.700.750.817 – oncogene protein v-maf MeSH D12.776.964.700.750.875 – oncogene proteins v-abl MeSH D12.776.964.700.750.882 – oncogene proteins v-erba MeSH D12.776.964.700.750.883 – oncogene proteins v-erbb MeSH D12.776.964.700.750.887 – oncogene proteins v-fos MeSH D12.776.964.700.750.900 – oncogene proteins v-mos MeSH D12.776.964.700.750.903 – oncogene proteins v-myb MeSH D12.776.964.700.750.920 – oncogene proteins v-raf MeSH D12.776.964.700.750.925 – oncogene proteins v-rel MeSH D12.776.964.700.750.935 – oncogene proteins v-sis
== History == Flutamide was first synthesized in 1967 by Neri and colleagues at Schering Plough Corporation. It was originally synthesized as a bacteriostatic agent, but was subsequently, and serendipitously found to possess antiandrogen activity. The code name of flutamide during development was SCH-13521. Clinical research of the medication began in 1971, and it was first marketed in 1983, specifically in Chile under the brand name Drogenil and in West Germany under the brand name Flugerel. Flutamide was not introduced in the United States until 1989; it was specifically approved by the U.S. Food and Drug Administration for the treatment of metastatic prostate cancer in combination with a gonadotropin-releasing hormone (GnRH) analogue. The medication was first studied for the treatment of hirsutism in women in 1989. It was the first "pure antiandrogen" to be studied in the treatment of hirsutism. Flutamide was the first NSAA to be introduced, and was followed by nilutamide in 1989 and then bicalutamide in 1995.
== Historical timeline == 1895 Wilhelm Conrad Röntgen discovers X-rays ("bremsstrahlung", from German for radiation produced by deceleration) 1896 Antoine Henri Becquerel discovers natural radioactivity; Minck proposes the therapeutic use 1904 Samuel Prescott describes the bactericide effects Massachusetts Institute of Technology (MIT) 1906 Appleby & Banks: UK patent to use radioactive isotopes to irradiate particulate food in a flowing bed 1918 Gillett: U.S. Patent to use X-rays for the preservation of food 1921 Schwartz describes the elimination of Trichinella from food 1930 Wuest: French patent on food irradiation 1943 MIT becomes active in the field of food preservation for the U.S. Army 1951 U.S. Atomic Energy Commission begins to co-ordinate national research activities 1958 World first commercial food irradiation (spices) at Stuttgart, Germany 1963 FDA approves food irradiation. NASA begins irradiating astronaut food items to prevent food borne illness during space missions.
The colonial government in South West Africa (present-day Namibia), from 1904 to 1908, carried out the annihilation of the local Herero and Nama peoples as punishment for an uprising; this was the 20th century's first genocide. The assassination of Austria's crown prince on 28 June 1914 provided the pretext for Austria-Hungary to attack Serbia and trigger World War I. After four years of warfare, in which approximately two million German soldiers were killed, a general armistice ended the fighting. In the German Revolution (November 1918), Wilhelm II and the ruling princes abdicated their positions.
Sources: en.wikipedia.org
β-Neoendorphin is an endogenous opioid peptide with a nonapeptide structure and the amino acid sequence Tyr-Gly-Gly-Phe-Leu-Arg-Lys-Tyr-Pro (YGGFLRKYP). It's one of the two neoendorphins. β-Neoendorphins (β-NEP) have the capability to stimulate wound healing by accelerating keratinocyte migration. This is achieved by β-NEP's activation of mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinases 1 and 2 (ERK 1 and ERK 2); along with the upregulation of matrix metalloproteinase 2 and 9 (MMP-2 and MMP-9). Wound healing by β-NEP results in migration without consequences on proliferation in human keratinocytes.
== Specificity == Retinal dehydrogenases are a subset of a larger family called aldehyde dehydrogenases. In particular, the three enzymes of the ALDH1A subfamily ALDH1A1 (aka RALDH1), ALDH1A2 (aka RALDH2), and ALDH1A3 (aka RALDH3) are known to preferentially act on retinal. While at least 19 different varieties of aldehyde dehydrogenases have been found in humans, many of them (like ALDH2) show little affinity for retinal. The size of the entrance tunnel to the enzyme active site appears to provide the specificity observed in ALDH1A1 for retinal as a substrate. The solvent-accessible diameter of the entrance tunnel is 150 Å3 in ALDH1A1, so the relatively large retinal can be accommodated while the solvent accessible diameter in ALDH2 is only 20 Å3 which limits accessibility to retinal but amply accommodates acetaldehyde.
== Natural occurrence == Naturally occurring fusion genes are most commonly created when a chromosomal translocation replaces the terminal exons of one gene with intact exons from a second gene. This creates a single gene that can be transcribed, spliced, and translated to produce a functional fusion protein. Many important cancer-promoting oncogenes are fusion genes produced in this way. Examples include:
== Measurement techniques == GDGTs are identified via organic geochemical analysis as the polar head groups of the membrane lipids. High-precision liquid chromatography mass spectrometry (HPLC-MS) is the primary means by which GDGTs are analyzed due to this method's tolerance for high temperatures.
The initial development of the cell marked the passage from prebiotic chemistry to partitioned units resembling modern cells. The final transition to living entities that fulfill all the definitions of modern cells depended on the ability to evolve effectively by natural selection. This transition has been called the Darwinian transition. If life is viewed from the point of view of replicator molecules, cells satisfy two fundamental conditions: protection from the outside environment and confinement of biochemical activity. The former condition is needed to keep complex molecules stable in a varying and sometimes reactive environment; the latter is fundamental for the evolution of biocomplexity. If freely floating molecules that code for enzymes are not enclosed in cells, the enzymes will automatically benefit neighboring replicator molecules as well. Thus, the consequences of diffusion in non-partitioned lifeforms would result in "parasitism by default." Therefore, the selection pressure on replicator molecules will be lower, as the 'lucky' molecule that produces the better enzyme does not fully leverage its advantage over its close neighbors. In contrast, if the molecule is enclosed in a cell membrane, the enzymes coded will be available only to itself. That molecule will uniquely benefit from the enzymes it codes for, increasing individuality and thus accelerating natural selection. Partitioning may have begun from cell-like spheroids formed by proteinoids, which are observed by heating amino acids with phosphoric acid as a catalyst.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.